Trust reports 6.5% stake in Coherus Oncology
Coherus Oncology, Inc. received a Schedule 13G reporting that the Timothy G. Youngquist 2020 Irrevocable Trust beneficially owns 7,850,800 shares of its common stock.
Rhea-AI Filing Summary
Coherus Oncology, Inc. received a Schedule 13G reporting that the Timothy G. Youngquist 2020 Irrevocable Trust beneficially owns 7,850,800 shares of its common stock. This represents 6.49% of the outstanding common shares, based on 120,871,013 shares outstanding as of October 31, 2025.
The trust has sole power to vote and dispose of these 7,850,800 shares. The position includes 560,000 shares underlying call options that are counted as beneficially owned because they are exercisable within 60 days. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Coherus.
Positive
- None.
Negative
- None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in Coherus (CHRS) is reported by the Timothy G. Youngquist 2020 Irrevocable Trust?
How was the 6.49% ownership percentage in Coherus (CHRS) calculated in this Schedule 13G?
Does the Coherus (CHRS) Schedule 13G include options in the reported ownership?
Is the reported Coherus (CHRS) stake intended to influence control of the company?
AI-generated analysis. How Rhea-AI works. Not financial advice.